

Johan Frostegard

List of Publications by Year in Descending Order

Source: <https://exaly.com/author-pdf/4104649/johan-frostegard-publications-by-year.pdf>

Version: 2024-04-28

This document has been generated based on the publications and citations recorded by exaly.com. For the latest version of this publication list, visit the link given above.

The third column is the impact factor (IF) of the journal, and the fourth column is the number of citations of the article.

112
papers

6,439
citations

41
h-index

79
g-index

121
ext. papers

7,159
ext. citations

5.6
avg, IF

5.97
L-index

#	Paper	IF	Citations
112	Antibodies Against Phosphorylcholine Among 60-Year-Olds: Clinical Role and Simulated Interactions.. <i>Frontiers in Cardiovascular Medicine</i> , 2022 , 9, 809007	5.4	1
111	The role of PCSK9 in inflammation, immunity, and autoimmune diseases.. <i>Expert Review of Clinical Immunology</i> , 2021 , 1-8	5.1	2
110	Antibodies against phosphorylcholine in hospitalized versus non-hospitalized obese subjects. <i>Scientific Reports</i> , 2021 , 11, 20246	4.9	0
109	Potential natural immunization against atherosclerosis in hibernating bears. <i>Scientific Reports</i> , 2021 , 11, 12120	4.9	3
108	Effects of Atorvastatin on T-Cell Activation and Apoptosis in Systemic Lupus Erythematosus and Novel Simulated Interactions With C-Reactive Protein and Interleukin 6. <i>ACR Open Rheumatology</i> , 2021 , 3, 642-653	3.5	2
107	Higher levels of anti-phosphorylcholine autoantibodies in early rheumatoid arthritis indicate lower risk of incident cardiovascular events. <i>Arthritis Research and Therapy</i> , 2021 , 23, 201	5.7	0
106	Integrative Analysis Reveals a Molecular Stratification of Systemic Autoimmune Diseases. <i>Arthritis and Rheumatology</i> , 2021 , 73, 1073-1085	9.5	27
105	Identification of IgG1 isotype phosphorylcholine antibodies for the treatment of inflammatory cardiovascular diseases. <i>Journal of Internal Medicine</i> , 2021 , 290, 141-156	10.8	6
104	Low levels of PCSK9 are associated with remission in patients with rheumatoid arthritis treated with anti-TNF- α potential underlying mechanisms. <i>Arthritis Research and Therapy</i> , 2021 , 23, 32	5.7	6
103	An elevated polyclonal free light chain level reflects a strong interferon signature in patients with systemic autoimmune diseases. <i>Journal of Translational Autoimmunity</i> , 2021 , 4, 100090	4.1	5
102	Patients with SLE have higher risk of cardiovascular events and mortality in comparison with controls with the same levels of traditional risk factors and intima-media measures, which is related to accumulated disease damage and antiphospholipid syndrome: a case-control study over 10 years. <i>Scientific Reports</i> , 2021 , 11, 19222	4.6	5
101	Immunoglobulin G1 Antibodies Against Phosphorylcholine Are Associated With Protection in Systemic Lupus Erythematosus and Atherosclerosis: Potential Underlying Mechanisms. <i>ACR Open Rheumatology</i> , 2020 , 2, 344-356	3.5	3
100	Proprotein convertase subtilisin kexin 9 is associated with disease activity and is implicated in immune activation in systemic lupus erythematosus. <i>Lupus</i> , 2020 , 29, 825-835	2.6	9
99	Different subclasses and isotypes of antibodies against phosphorylcholine in haemodialysis patients: association with mortality. <i>Clinical and Experimental Immunology</i> , 2020 , 201, 94-104	6.2	4
98	Antibodies against Malondialdehyde in Haemodialysis Patients and Its Association with Clinical Outcomes: Differences between Subclasses and Isotypes. <i>Journal of Clinical Medicine</i> , 2020 , 9,	5.1	3
97	Similar progression of carotid intima-media thickness in 7-year surveillance of patients with mild SLE and controls, but this progression is still promoted by dyslipidaemia, lower HDL levels, hypertension, history of lupus nephritis and a higher prednisolone usage in patients. <i>Lupus Science and Medicine</i> , 2020 , 7, e000362	4.6	8
96	IgM antibodies against malondialdehyde and phosphorylcholine in different systemic rheumatic diseases. <i>Scientific Reports</i> , 2020 , 10, 11010	4.9	2

95	SAT0026 HIGHER LEVELS OF NATURAL ANTI-PHOSPHORYLCHOLINE ANTIBODIES ARE ASSOCIATED WITH LOWER RISK OF INCIDENT CARDIOVASCULAR EVENTS IN YOUNGER PATIENTS WITH RHEUMATOID ARTHRITIS. <i>Annals of the Rheumatic Diseases</i> , 2020 , 79, 943.1-943	2.4	
94	Phenotypic features of vascular calcification in chronic kidney disease. <i>Journal of Internal Medicine</i> , 2020 , 287, 422-434	10.8	6
93	Antiphospholipid autoantibody detection is important in all patients with systemic autoimmune diseases. <i>Journal of Autoimmunity</i> , 2020 , 115, 102524	15.5	4
92	Antibodies against Phosphorylcholine and Malondialdehyde during the First Two Years of Life. <i>Journal of Immunology</i> , 2020 , 205, 2109-2116	5.3	3
91	C-reactive protein in traditional melanesians on Kitava. <i>BMC Cardiovascular Disorders</i> , 2020 , 20, 524	2.3	1
90	Malondialdehyde Conjugated With Albumin Induces Pro-Inflammatory Activation of T Cells Isolated From Human Atherosclerotic Plaques Both Directly and Via Dendritic Cell-Mediated Mechanism. <i>JACC Basic To Translational Science</i> , 2019 , 4, 480-494	8.7	5
89	Variation in pain related to systemic lupus erythematosus (SLE): a 7-year follow-up study. <i>Clinical Rheumatology</i> , 2018 , 37, 1825-1834	3.9	10
88	PCSK9 plays a novel immunological role in oxidized LDL-induced dendritic cell maturation and activation of T cells from human blood and atherosclerotic plaque. <i>Journal of Internal Medicine</i> , 2018 , 284, 193	10.8	34
87	A genome-wide association study of IgM antibody against phosphorylcholine: shared genetics and phenotypic relationship to chronic lymphocytic leukemia. <i>Human Molecular Genetics</i> , 2018 , 27, 1809-1818	5.6	3
86	Autoantibody profiling reveals four protein candidate autoantigens associated with systemic lupus erythematosus. <i>Lupus</i> , 2018 , 27, 1670-1678	2.6	5
85	IgM antibodies against phosphorylcholine promote polarization of T regulatory cells from patients with atherosclerotic plaques, systemic lupus erythematosus and healthy donors. <i>Atherosclerosis</i> , 2018 , 268, 36-48	3.1	24
84	Association between dietary and metabolic factors and IgM antibodies to phosphorylcholine and malondialdehyde in patients with systemic lupus erythematosus and population-based matched controls. <i>Clinical and Experimental Rheumatology</i> , 2018 , 36, 428-433	2.2	3
83	IgM antibodies to oxidized phosphatidylserine as protection markers in cardiovascular disease among 60-year olds. <i>PLoS ONE</i> , 2017 , 12, e0171195	3.7	3
82	Transancestral mapping and genetic load in systemic lupus erythematosus. <i>Nature Communications</i> , 2017 , 8, 16021	17.4	171
81	Induction of Dendritic Cell-Mediated Activation of T Cells From Atherosclerotic Plaques by Human Heat Shock Protein 60. <i>Journal of the American Heart Association</i> , 2017 , 6,	6	19
80	Antibodies against Phosphorylcholine among New Guineans Compared to Swedes: An Aspect of the Hygiene/Missing Old Friends Hypothesis. <i>Immunological Investigations</i> , 2017 , 46, 59-69	2.9	10
79	Oxidized Low-Density Lipoprotein (OxLDL)-Treated Dendritic Cells Promote Activation of T Cells in Human Atherosclerotic Plaque and Blood, Which Is Repressed by Statins: microRNA let-7c Is Integral to the Effect. <i>Journal of the American Heart Association</i> , 2016 , 5,	6	48
78	The association between diet and glucocorticoid treatment in patients with SLE. <i>Lupus Science and Medicine</i> , 2016 , 3, e000135	4.6	5

77	Dietary micronutrient intake and atherosclerosis in systemic lupus erythematosus. <i>Lupus</i> , 2016 , 25, 1602-1609	7	1609
76	Human IgM Antibodies to Malondialdehyde Conjugated With Albumin Are Negatively Associated With Cardiovascular Disease Among 60-Year-Olds. <i>Journal of the American Heart Association</i> , 2016 , 5,	6	14
75	IgM antibodies against malondialdehyde and phosphorylcholine are together strong protection markers for atherosclerosis in systemic lupus erythematosus: Regulation and underlying mechanisms. <i>Clinical Immunology</i> , 2016 , 166-167, 27-37	9	48
74	Coenzyme Q10 and oxidative stress, the association with peripheral sensory neuropathy and cardiovascular disease in type 2 diabetes mellitus. <i>Journal of Diabetes and Its Complications</i> , 2015 , 29, 1152-8	3.2	11
73	Induction of dendritic cell-mediated T-cell activation by modified but not native low-density lipoprotein in humans and inhibition by annexin a5: involvement of heat shock proteins. <i>Arteriosclerosis, Thrombosis, and Vascular Biology</i> , 2015 , 35, 197-205	9.4	39
72	AB0617 Bone Mineral Density and Carotid Atherosclerosis in Systemic Lupus Erythematosus: A Controlled Cross-Sectional Study. <i>Annals of the Rheumatic Diseases</i> , 2015 , 74, 1105.3-1106	2.4	
71	Bone mineral density and carotid atherosclerosis in systemic lupus erythematosus: a controlled cross-sectional study. <i>Arthritis Research and Therapy</i> , 2015 , 17, 84	5.7	21
70	Prediction and management of cardiovascular outcomes in systemic lupus erythematosus. <i>Expert Review of Clinical Immunology</i> , 2015 , 11, 247-53	5.1	10
69	PXK locus in systemic lupus erythematosus: fine mapping and functional analysis reveals novel susceptibility gene ABHD6. <i>Annals of the Rheumatic Diseases</i> , 2015 , 74, e14	2.4	20
68	Low levels of IgM antibodies against phosphorylcholine are associated with fast carotid intima media thickness progression and cardiovascular risk in men. <i>Atherosclerosis</i> , 2014 , 236, 394-9	3.1	19
67	Naturally occurring human phosphorylcholine antibodies are predominantly products of affinity-matured B cells in the adult. <i>Journal of Immunology</i> , 2014 , 192, 4551-9	5.3	30
66	Oxidized but not native cardiolipin has pro-inflammatory effects, which are inhibited by Annexin A5. <i>Atherosclerosis</i> , 2014 , 235, 592-8	3.1	33
65	AB0119 Fully Human Monoclonal Antibodies to Phosphorylcholine Inhibit Basal and Tnf-Induced IL-6 and ICAM-1 in Synovial-Like Fibroblasts from A Rheumatoid Arthritis. <i>Annals of the Rheumatic Diseases</i> , 2014 , 73, 843.2-843	2.4	
64	IgM-antibodies against phosphorylcholine in mothers and normal or low birth weight term newborn infants. <i>PLoS ONE</i> , 2014 , 9, e106584	3.7	3
63	Antibodies against native and oxidized cardiolipin and phosphatidylserine and phosphorylcholine in atherosclerosis development. <i>PLoS ONE</i> , 2014 , 9, e111764	3.7	7
62	Immunity, atherosclerosis and cardiovascular disease. <i>BMC Medicine</i> , 2013 , 11, 117	11.4	423
61	IgM-phosphorylcholine autoantibodies and outcome in acute coronary syndromes. <i>International Journal of Cardiology</i> , 2013 , 167, 464-9	3.2	34
60	Low levels of IgM antibodies to oxidized cardiolipin increase and high levels decrease risk of cardiovascular disease among 60-year olds: a prospective study. <i>BMC Cardiovascular Disorders</i> , 2013 , 13, 1	2.3	23

59	Annexin A5 inhibits atherogenic and pro-inflammatory effects of lysophosphatidylcholine. <i>Prostaglandins and Other Lipid Mediators</i> , 2013 , 106, 72-8	3.7	17
58	Immune mechanisms in atherosclerosis, especially in diabetes type 2. <i>Frontiers in Endocrinology</i> , 2013 , 4, 162	5.7	30
57	Low levels of antibodies against oxidized but not nonoxidized cardiolipin and phosphatidylserine are associated with atherosclerotic plaques in systemic lupus erythematosus. <i>Journal of Rheumatology</i> , 2013 , 40, 1856-64	4.1	13
56	Immunoglobulin (Ig)M antibodies against oxidized cardiolipin but not native cardiolipin are novel biomarkers in haemodialysis patients, associated negatively with mortality. <i>Clinical and Experimental Immunology</i> , 2013 , 174, 441-8	6.2	4
55	AB1421-HPR Using the SF-MCGILL pain questionnaire, how do patients with SLE describe their pain?. <i>Annals of the Rheumatic Diseases</i> , 2013 , 71, 756.3-756	2.4	
54	IgM phosphorylcholine antibodies inhibit cell death and constitute a strong protection marker for atherosclerosis development, particularly in combination with other auto-antibodies against modified LDL. <i>Results in Immunology</i> , 2012 , 2, 13-8		31
53	Geographical differences in autoantibodies and anti-infectious agents antibodies among healthy adults. <i>Clinical Reviews in Allergy and Immunology</i> , 2012 , 42, 154-63	12.3	45
52	Genetic and environmental regulation of inflammatory CVD biomarkers Lp-PLA2 and IgM anti-PC. <i>Atherosclerosis</i> , 2011 , 218, 117-22	3.1	13
51	Cardiovascular co-morbidity in patients with rheumatic diseases. <i>Arthritis Research and Therapy</i> , 2011 , 13, 225	5.7	9
50	Longitudinal levels of apolipoproteins and antibodies against phosphorylcholine are independently associated with carotid artery atherosclerosis 5 years after rheumatoid arthritis onset--a prospective cohort study. <i>Rheumatology</i> , 2011 , 50, 1785-93	3.9	21
49	Annexin A5 therapy attenuates vascular inflammation and remodeling and improves endothelial function in mice. <i>Arteriosclerosis, Thrombosis, and Vascular Biology</i> , 2011 , 31, 95-101	9.4	60
48	Effect of biological therapy on levels of atheroprotective antibodies against phosphorylcholine and apolipoproteins in rheumatoid arthritis - a one year study. <i>Clinical and Experimental Rheumatology</i> , 2011 , 29, 942-50	2.2	13
47	Low levels of antibodies against phosphorylcholine in Alzheimer's disease. <i>Journal of Alzheimer's Disease</i> , 2010 , 21, 577-84	4.3	11
46	Rheumatic diseases: insights into inflammation and atherosclerosis. <i>Arteriosclerosis, Thrombosis, and Vascular Biology</i> , 2010 , 30, 892-3	9.4	13
45	Low levels of antibodies against phosphorylcholine predict development of stroke in a population-based study from northern Sweden. <i>Stroke</i> , 2010 , 41, 607-12	6.7	53
44	Low levels of IgM antibodies to phosphorylcholine predict cardiovascular disease in 60-year old men: effects on uptake of oxidized LDL in macrophages as a potential mechanism. <i>Journal of Autoimmunity</i> , 2010 , 34, 73-9	15.5	84
43	Increased prevalence of vulnerable atherosclerotic plaques and low levels of natural IgM antibodies against phosphorylcholine in patients with systemic lupus erythematosus. <i>Arthritis Research and Therapy</i> , 2010 , 12, R214	5.7	84
42	Effects of anti-cardiolipin antibodies and IVIg on annexin A5 binding to endothelial cells: implications for cardiovascular disease. <i>Scandinavian Journal of Rheumatology</i> , 2010 , 39, 77-83	1.9	13

41	Low level natural antibodies against phosphorylcholine: a novel risk marker and potential mechanism in atherosclerosis and cardiovascular disease. <i>Clinical Immunology</i> , 2010 , 134, 47-54	9	68
40	Natural antibodies against phosphorylcholine in cardiovascular disease. <i>Annals of the New York Academy of Sciences</i> , 2009 , 1173, 292-300	6.5	47
39	Antitreponemal antibodies leading to autoantibody production and protection from atherosclerosis in Kitavans from Papua New Guinea. <i>Annals of the New York Academy of Sciences</i> , 2009 , 1173, 675-82	6.5	19
38	Low levels of IgM antibodies against phosphorylcholine predict development of acute myocardial infarction in a population-based cohort from northern Sweden. <i>European Journal of Cardiovascular Prevention and Rehabilitation</i> , 2009 , 16, 382-6		52
37	Low levels of IgM antibodies against phosphorylcholine-A increase mortality risk in patients undergoing haemodialysis. <i>Nephrology Dialysis Transplantation</i> , 2009 , 24, 3454-60	4.3	24
36	Low levels of IgM antibodies against phosphorylcholine-A potential risk marker for ischemic stroke in men. <i>Atherosclerosis</i> , 2009 , 203, 528-32	3.1	69
35	Gluten-free vegan diet induces decreased LDL and oxidized LDL levels and raised atheroprotective natural antibodies against phosphorylcholine in patients with rheumatoid arthritis: a randomized study. <i>Arthritis Research and Therapy</i> , 2008 , 10, R34	5.7	63
34	Systemic lupus erythematosus and cardiovascular disease. <i>Lupus</i> , 2008 , 17, 364-7	2.6	38
33	Natural antibodies against phosphorylcholine as potential protective factors in SLE. <i>Rheumatology</i> , 2008 , 47, 1144-50	3.9	93
32	Atheroprotective natural anti-phosphorylcholine antibodies of IgM subclass are decreased in Swedish controls as compared to non-westernized individuals from New Guinea. <i>Nutrition and Metabolism</i> , 2007 , 4, 7	4.6	39
31	Effects of low-dose prednisolone on endothelial function, atherosclerosis, and traditional risk factors for atherosclerosis in patients with rheumatoid arthritis--a randomized study. <i>Journal of Rheumatology</i> , 2007 , 34, 1810-6	4.1	79
30	Antibodies of IgM subclass to phosphorylcholine and oxidized LDL are protective factors for atherosclerosis in patients with hypertension. <i>Atherosclerosis</i> , 2006 , 188, 160-6	3.1	145
29	Atherosclerosis in patients with autoimmune disorders. <i>Arteriosclerosis, Thrombosis, and Vascular Biology</i> , 2005 , 25, 1776-85	9.4	172
28	Annexin A5 in cardiovascular disease and systemic lupus erythematosus. <i>Immunobiology</i> , 2005 , 210, 761-84	3.4	30
27	SLE, atherosclerosis and cardiovascular disease. <i>Journal of Internal Medicine</i> , 2005 , 257, 485-95	10.8	95
26	Lipid peroxidation is enhanced in patients with systemic lupus erythematosus and is associated with arterial and renal disease manifestations. <i>Arthritis and Rheumatism</i> , 2005 , 52, 192-200		180
25	Heat Shock Protein Release and Naturally Occurring Exogenous Heat Shock Proteins 2005 , 195-219		4
24	Decreased binding of annexin v to endothelial cells: a potential mechanism in atherothrombosis of patients with systemic lupus erythematosus. <i>Arteriosclerosis, Thrombosis, and Vascular Biology</i> , 2005 , 25, 198-203	9.4	74

23	Risk factors for cardiovascular disease in patients with periodontitis. <i>European Heart Journal</i> , 2003 , 24, 2099-107	9.5	168
22	Circulating oxidized low-density lipoprotein is increased in hypertension. <i>Clinical Science</i> , 2003 , 105, 615-619	4.8	48
21	Elevated triglycerides and low levels of high-density lipoprotein as markers of disease activity in association with up-regulation of the tumor necrosis factor alpha/tumor necrosis factor receptor system in systemic lupus erythematosus. <i>Arthritis and Rheumatism</i> , 2003 , 48, 2533-40		116
20	Oxidised LDL modulates immune-activation by an IL-12 dependent mechanism. <i>Atherosclerosis</i> , 2003 , 169, 77-85	3.1	23
19	TNF-alpha: a link between hypertriglyceridaemia and inflammation in SLE patients with cardiovascular disease. <i>Lupus</i> , 2003 , 12, 454-61	2.6	113
18	Serum heat shock protein 70 levels predict the development of atherosclerosis in subjects with established hypertension. <i>Hypertension</i> , 2003 , 42, 235-8	8.5	194
17	Autoimmunity, oxidized LDL and cardiovascular disease. <i>Autoimmunity Reviews</i> , 2002 , 1, 233-7	13.6	78
16	Risk factors for cardiovascular disease in systemic lupus erythematosus. <i>Circulation</i> , 2001 , 104, 1887-93	16.7	397
15	Circulating heat shock protein 60 is associated with early cardiovascular disease. <i>Hypertension</i> , 2000 , 36, 303-7	8.5	220
14	Induction of early atherosclerosis in CBA/J mice by combination of Trypanosoma cruzi infection and a high cholesterol diet. <i>Atherosclerosis</i> , 2000 , 153, 273-82	3.1	17
13	Autoantibodies to OxLDL are decreased in individuals with borderline hypertension. <i>Hypertension</i> , 1999 , 33, 53-9	8.5	99
12	Lysophosphatidylcholine (LPC) induces proinflammatory cytokines by a platelet-activating factor (PAF) receptor-dependent mechanism. <i>Clinical and Experimental Immunology</i> , 1999 , 116, 326-31	6.2	127
11	Cytokine expression in advanced human atherosclerotic plaques: dominance of pro-inflammatory (Th1) and macrophage-stimulating cytokines. <i>Atherosclerosis</i> , 1999 , 145, 33-43	3.1	770
10	Antibodies to endothelial cells in borderline hypertension. <i>Circulation</i> , 1998 , 98, 1092-8	16.7	44
9	Association of serum antibodies to heat-shock protein 65 with borderline hypertension. <i>Hypertension</i> , 1997 , 29, 40-4	8.5	60
8	Expression of phospholipase A2 isoforms in human normal and atherosclerotic arterial wall. <i>Arteriosclerosis, Thrombosis, and Vascular Biology</i> , 1997 , 17, 2257-63	9.4	102
7	Platelet-activating factor and oxidized LDL induce immune activation by a common mechanism. <i>Arteriosclerosis, Thrombosis, and Vascular Biology</i> , 1997 , 17, 963-8	9.4	79
6	Induction of heat shock protein in monocytic cells by oxidized low density lipoprotein. <i>Atherosclerosis</i> , 1996 , 121, 93-103	3.1	84

5	Oxidized LDL induces enhanced antibody formation and MHC class II-dependent IFN-gamma production in lymphocytes from healthy individuals. <i>Arteriosclerosis, Thrombosis, and Vascular Biology</i> , 1995 , 15, 1577-83	9.4	52
4	Induction of T-cell activation by oxidized low density lipoprotein. <i>Arteriosclerosis and Thrombosis: A Journal of Vascular Biology</i> , 1992 , 12, 461-7		196
3	Biologically modified LDL increases the adhesive properties of endothelial cells. <i>Atherosclerosis</i> , 1991 , 90, 119-26	3.1	150
2	Oxidized low density lipoprotein induces differentiation and adhesion of human monocytes and the monocytic cell line U937. <i>Proceedings of the National Academy of Sciences of the United States of America</i> , 1990 , 87, 904-8	11.5	285
1	Low density lipoprotein-induced growth of U937 cells: a novel method to determine the receptor binding of low density lipoprotein. <i>Journal of Lipid Research</i> , 1990 , 31, 37-44	6.3	25